Vasoactive intestinal polypeptide receptor 2

BE0013151ProteinHumansVIPR2

G protein-coupled receptor activated by the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (ADCYAP1/PACAP) (PubMed:7811244, PubMed:35477937, PubMed:8933357). It is acted on by 1 drug in DrugBank.

Gene name
VIPR2
UniProtKB entry
P41587Swiss-Prot
Cellular location
Cell membrane
Residues / weight
438 residues · 49,478 Da
Also known as
Helodermin-preferring VIP receptor · PACAP type III receptor · PACAP-R-3 · PACAP-R3 · Pituitary adenylate cyclase-activating polypeptide type III receptor

Resolves to

Protein
UniProtP41587UniProt nameVIPR2_HUMAN
Gene
HGNCHGNC:12695NCBI Gene7434GeneCardsVIPR2
Pharmacology
IUPHAR/GtoPdb372KEGGhsa:7434
Structure
PDB2X57PDB7VQXPDB7WBJ
Drugs

What you can answer from here — as of September 03, 2024

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
11GO termsFunction, process and component, as structured annotations
Sign in
2Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which compounds in development act on Vasoactive intestinal polypeptide receptor 2, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In